We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Regeneron has won Emergency Use Authorization (EUA) from the FDA for its investigational antibody cocktail for the treatment of patients with mild-to-moderate COVID-19 symptoms at high risk of severe disease progression or hospitalization — and an initial 30,000 doses are expected to ship today. Read More
Pfizer has released promising results from a global phase 3 trial of its non-small cell lung cancer (NSCLC) investigational treatment, Lorbrena (lorlatinib). Read More
The FDA has granted an Emergency Use Authorization (EUA) for Eli Lilly’s rheumatoid arthritis drug Olumiant (baricitinib) in combination with Gilead Sciences’ antiviral Veklury (remdesivir) for treatment of COVID-19 patients needing supplemental oxygen. Read More
The study involved 4,566 men who have sex with men and spanned research sites in the U.S., Argentina, Brazil, Peru, South Africa, Thailand and Vietnam. Read More
The drug previously received Orphan Status from the FDA and the European Medicines Agency for other muscular degenerative diseases, including a form of muscular dystrophy. Read More
The FDA has granted a priority review to Sanofi’s biologics license application (BLA) for an experimental enzyme replacement therapy for patients suffering from Pompe disease, a rare illness that causes muscle deterioration and reduced lung capacity. Read More
The European Commission has approved AstraZeneca’s leukemia drug Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL). Read More